AR075517A1 - Derivados de isoxazol-isoxazol y de isoxazol-isotiazol - Google Patents
Derivados de isoxazol-isoxazol y de isoxazol-isotiazolInfo
- Publication number
- AR075517A1 AR075517A1 ARP100100476A ARP100100476A AR075517A1 AR 075517 A1 AR075517 A1 AR 075517A1 AR P100100476 A ARP100100476 A AR P100100476A AR P100100476 A ARP100100476 A AR P100100476A AR 075517 A1 AR075517 A1 AR 075517A1
- Authority
- AR
- Argentina
- Prior art keywords
- lower alkyl
- halogen
- alkoxy
- hydroxy
- optionally substituted
- Prior art date
Links
- FCDRINPELRTVHD-UHFFFAOYSA-N 1,2-oxazole Chemical class C=1C=NOC=1.C=1C=NOC=1 FCDRINPELRTVHD-UHFFFAOYSA-N 0.000 title abstract 2
- 125000000217 alkyl group Chemical group 0.000 abstract 22
- 125000003545 alkoxy group Chemical group 0.000 abstract 5
- -1 cyano, hydroxy Chemical group 0.000 abstract 5
- 229910052736 halogen Inorganic materials 0.000 abstract 5
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 4
- 125000000623 heterocyclic group Chemical group 0.000 abstract 4
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000005843 halogen group Chemical group 0.000 abstract 3
- 125000001072 heteroaryl group Chemical group 0.000 abstract 3
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 abstract 2
- 150000001875 compounds Chemical class 0.000 abstract 2
- 150000002367 halogens Chemical group 0.000 abstract 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 2
- OLROCKKMZHTZFM-UHFFFAOYSA-N 1,2-oxazole;1,2-thiazole Chemical class C=1C=NOC=1.C=1C=NSC=1 OLROCKKMZHTZFM-UHFFFAOYSA-N 0.000 abstract 1
- 208000024827 Alzheimer disease Diseases 0.000 abstract 1
- 208000010877 cognitive disease Diseases 0.000 abstract 1
- 239000002475 cognitive enhancer Substances 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229960003692 gamma aminobutyric acid Drugs 0.000 abstract 1
- BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 abstract 1
- 125000004438 haloalkoxy group Chemical group 0.000 abstract 1
- 229910052757 nitrogen Inorganic materials 0.000 abstract 1
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 abstract 1
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 1
- 238000011321 prophylaxis Methods 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D261/00—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings
- C07D261/02—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings
- C07D261/06—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members
- C07D261/10—Heterocyclic compounds containing 1,2-oxazole or hydrogenated 1,2-oxazole rings not condensed with other rings having two or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D261/18—Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/42—Oxazoles
- A61K31/422—Oxazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/04—Centrally acting analgesics, e.g. opioids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Pain & Pain Management (AREA)
- Anesthesiology (AREA)
- Psychology (AREA)
- Addiction (AREA)
- Hospice & Palliative Care (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
Abstract
La presente invencion se refiere a derivados de isoxazol-isoxazol y de isoxazol-isotiazol, que tienen afinidad y selectividad por el receptor de GABA A alfa5, a su obtencion, a composiciones farmacéuticas que los contienen y a su utilizacion como medicamentos. Los compuestos activos de la presente invencion utiles como intensificadores cognitivos o para el tratamiento terapéutico y/o profiláctico, de trastornos cognitivos como la enfermedad de Alzheimer. Reivindicacion 1: Compuestos de la formula (1), en la que es alquilo inferior, opcionalmente sustituido por halogeno, ciano, hidroxi, alcoxi inferior o halogeno-alcoxi inferior; arilo, heteroarilo, cicloalquilo, heterociclilo; cada uno de ellos está opcionalmente sustituido por halogeno, ciano, hidroxi, alquilo inferior, halogeno-alquilo inferior, ciano-alquilo inferior, hidroxi-alquilo inferior, (alquilo inferior)-C(=O)OH, (alquilo inferior)-C(=O)O-alquilo inferior, alquilo inferior)-CO-NR5R6, (alquilo inferior)-NR5R6, alcoxi inferior-alquilo inferior, -CO-alquilo inferior, -C(=O)OH, -C(=O)O-alquilo inferior, -CONR5R6, -NR5R6, alcoxi inferior, halogeno-alcoxi inferior, -SO2-alquilo inferior, -SO2-NR5R6, cicloalquilo, feniloxi o fenilo, R2 es alquilo inferior opcionalmente sustituido por halogeno, ciano, hidroxi, alcoxi inferior o halogeno-alcoxi inferior, R3 es alquilo inferior, opcionalmente sustituido por carboxi, halogeno o hidroxilo; arilo, heteroarilo, cicloalquilo, heterociclilo; cada arilo, heteroarilo, cicloalquilo, heterociclilo está opcionalmente sustituido por carboxi, halogeno, hidroxi o alquilo inferior; o -NR7R8, R4 es H o alquilo inferior, o R3 y R4 junto con el nitrogeno al que están unidos forman un anillo heterocíclico, R5 es H o alquilo inferior, R6 es H o alquilo inferior, R7 es H o alquilo inferior, R8 es H o alquilo inferior, Y es O o S, X es CH2-O- o -CH=CH-, o sus sales o ésteres farmacéuticamente activos.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP09153162 | 2009-02-19 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR075517A1 true AR075517A1 (es) | 2011-04-06 |
Family
ID=42111584
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP100100476A AR075517A1 (es) | 2009-02-19 | 2010-02-18 | Derivados de isoxazol-isoxazol y de isoxazol-isotiazol |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US8173652B2 (es) |
| EP (1) | EP2398782B1 (es) |
| JP (1) | JP5478640B2 (es) |
| KR (1) | KR101361465B1 (es) |
| CN (1) | CN102317270B (es) |
| AR (1) | AR075517A1 (es) |
| AU (1) | AU2010215515A1 (es) |
| BR (1) | BRPI1016117A8 (es) |
| CA (1) | CA2749649C (es) |
| ES (1) | ES2431617T3 (es) |
| IL (1) | IL213974A0 (es) |
| MX (1) | MX2011007774A (es) |
| SG (1) | SG173666A1 (es) |
| TW (1) | TW201033201A (es) |
| WO (1) | WO2010094669A1 (es) |
Families Citing this family (20)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AP2014007805A0 (en) | 2011-12-28 | 2014-07-31 | Cytokinetics Inc The Regents Of The University Of California | Substituted benzaldehyde compounds and methods fortheir use in increasing tissue oxygenation |
| WO2013102145A1 (en) | 2011-12-28 | 2013-07-04 | Global Blood Therapeutics, Inc. | Substituted heteroaryl aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US20150374705A1 (en) | 2012-02-14 | 2015-12-31 | Shanghai Institues for Biological Sciences | Substances for treatment or relief of pain |
| ES2852054T3 (es) * | 2013-03-15 | 2021-09-10 | Global Blood Therapeutics Inc | Compuestos y usos de los mismos para la modulación de hemoglobina |
| AP2015008718A0 (en) | 2013-03-15 | 2015-09-30 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US9422279B2 (en) | 2013-03-15 | 2016-08-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US9458139B2 (en) | 2013-03-15 | 2016-10-04 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| US10266551B2 (en) | 2013-03-15 | 2019-04-23 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| MY180206A (en) | 2013-03-15 | 2020-11-25 | Global Blood Therapeutics Inc | Compounds and uses thereof for the modulation of hemoglobin |
| US10100043B2 (en) | 2013-03-15 | 2018-10-16 | Global Blood Therapeutics, Inc. | Substituted aldehyde compounds and methods for their use in increasing tissue oxygenation |
| US8952171B2 (en) | 2013-03-15 | 2015-02-10 | Global Blood Therapeutics, Inc. | Compounds and uses thereof for the modulation of hemoglobin |
| EA202092627A1 (ru) | 2013-11-18 | 2021-09-30 | Глобал Блад Терапьютикс, Инк. | Соединения и их применения для модуляции гемоглобина |
| SG10201911668VA (en) | 2014-02-07 | 2020-01-30 | Global Blood Therapeutics Inc | Crystalline polymorphs of the free base of 2-hydroxy-6-((2-(1-isopropyl-1h-pyrazol-5-yl)pyridin-3-yl)methoxy)benzaldehyde |
| HUE072191T2 (hu) | 2015-12-04 | 2025-10-28 | Global Blood Therapeutics Inc | A 2-hidoxi-6-((2-(1-izopropil-1H-pirazol-5-il)piridin-3-il)metoxi)benzaldehid adagolási rendje |
| TWI663160B (zh) | 2016-05-12 | 2019-06-21 | 全球血液治療公司 | 用於合成2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)-吡啶-3-基)甲氧基)苯甲醛之方法 |
| TW202332423A (zh) | 2016-10-12 | 2023-08-16 | 美商全球血液治療公司 | 包含2-羥基-6-((2-(1-異丙基-1h-吡唑-5-基)吡啶-3-基)甲氧基)-苯甲醛之片劑 |
| ES2966707T3 (es) | 2018-10-01 | 2024-04-23 | Global Blood Therapeutics Inc | Moduladores de la hemoglobina para el tratamiento de la drepanocitosis |
| CN113316568B (zh) | 2018-11-19 | 2024-11-08 | 全球血液疗法股份有限公司 | 能够调节血红蛋白的2-甲酰基-3-羟基苯基氧基甲基化合物 |
| US12479816B2 (en) | 2019-02-08 | 2025-11-25 | University of Pittsburgh—of the Commonwealth System of Higher Education | 20-HETE formation inhibitors |
| KR20240005848A (ko) | 2021-05-05 | 2024-01-12 | 유니버시티 칼리지 카디프 컨설턴츠 리미티드 | 인지 장애의 치료에 유용한 헤테로아릴 화합물 |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3525205A1 (de) | 1984-09-11 | 1986-03-20 | Hoechst Ag, 6230 Frankfurt | Pflanzenschuetzende mittel auf basis von 1,2,4-triazolderivaten sowie neue derivate des 1,2,4-triazols |
| GB9808663D0 (en) | 1998-04-23 | 1998-06-24 | Merck Sharp & Dohme | Therapeutic agents |
| US6660753B2 (en) | 1999-08-19 | 2003-12-09 | Nps Pharmaceuticals, Inc. | Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists |
| IT1314191B1 (it) | 1999-10-18 | 2002-12-06 | Recordati Chem Pharm | Derivati isossazolcarbossamidici |
| WO2001034603A2 (en) | 1999-11-12 | 2001-05-17 | Neurogen Corporation | Bicyclic and tricyclic heteroaromatic compounds |
| PA8535601A1 (es) | 2000-12-21 | 2002-11-28 | Pfizer | Derivados benzimidazol y piridilimidazol como ligandos para gabaa |
| GB0108475D0 (en) | 2001-04-04 | 2001-05-23 | Merck Sharp & Dohme | New compounds |
| EA005934B1 (ru) | 2001-07-05 | 2005-08-25 | Х. Лундбекк А/С | Замещённые анилиновые пиперидины в качестве селективных антагонистов мсн |
| DE60131967D1 (de) | 2001-08-13 | 2008-01-31 | Phenex Pharmaceuticals Ag | Nr1h4-kern-rezeptor-bindende verbindungen |
| EP1448561B1 (en) | 2001-11-20 | 2008-02-20 | Eli Lilly And Company | Beta 3 adrenergic agonists |
| GB0128160D0 (en) | 2001-11-23 | 2002-01-16 | Merck Sharp & Dohme | Novel compounds |
| EP1562915A1 (en) | 2002-11-22 | 2005-08-17 | SmithKline Beecham Corporation | Farnesoid x receptor agonists |
| GB0318447D0 (en) | 2003-08-05 | 2003-09-10 | Merck Sharp & Dohme | Therapeutic agents |
| EP1756086B1 (en) | 2004-06-01 | 2008-06-04 | F.Hoffmann-La Roche Ag | Pyridin-4-yl-ethynyl-imidazoles and pyrazoles as mglu5 receptor antagonists |
| EP1773807A2 (en) | 2004-06-14 | 2007-04-18 | Takeda San Diego, Inc. | Kinase inhibitors |
| CA2581945C (en) | 2004-10-01 | 2011-01-18 | Henrietta Dehmlow | Hexafluoroisopropanol substituted ether derivatives |
| US7351724B2 (en) | 2004-10-15 | 2008-04-01 | The Scripps Research Institute | Oxadiazole ketone inhibitors of fatty acid amide hydrolase |
| US20070060589A1 (en) | 2004-12-21 | 2007-03-15 | Purandare Ashok V | Inhibitors of protein arginine methyl transferases |
| EP1904337B1 (de) | 2005-07-20 | 2010-10-13 | Prospective Concepts AG | Pneumatisch verstellbare seitenwangen für fahrzeugsitze |
| DE602006003777D1 (de) * | 2005-09-19 | 2009-01-02 | Hoffmann La Roche | Isoxazolderivate als inverse gaba a alpha5 agonisten |
| EP1937674A1 (en) * | 2005-10-11 | 2008-07-02 | F.Hoffmann-La Roche Ag | Isoxazole derivatives |
| WO2007052843A1 (ja) | 2005-11-04 | 2007-05-10 | Takeda Pharmaceutical Company Limited | 複素環アミド化合物およびその用途 |
| JP5081161B2 (ja) | 2005-12-19 | 2012-11-21 | スミスクライン ビーチャム コーポレーション | ファルネソイドｘ受容体アゴニスト |
| WO2007071598A1 (en) * | 2005-12-23 | 2007-06-28 | F. Hoffmann-La Roche Ag | Aryl-isoxazolo-4-yl-oxadiazole derivatives |
| CN101351461B (zh) * | 2005-12-27 | 2011-09-07 | 弗·哈夫曼-拉罗切有限公司 | 芳基-异*唑-4-基-咪唑衍生物 |
| US7863302B2 (en) | 2006-02-03 | 2011-01-04 | Eli Lilly And Company | Compounds and methods for modulating FX-receptors |
| JP2007230909A (ja) | 2006-03-01 | 2007-09-13 | Univ Of Tokyo | 置換イソキサゾール誘導体 |
| CA2651857A1 (en) | 2006-05-31 | 2007-12-06 | F. Hoffmann-La Roche Ag | Aryl-4-ethynyl-isoxazole derivatives |
| EP1894924A1 (en) | 2006-08-29 | 2008-03-05 | Phenex Pharmaceuticals AG | Heterocyclic FXR binding compounds |
| EP1894928A1 (en) | 2006-08-29 | 2008-03-05 | PheneX Pharmaceuticals AG | Heterocyclic fxr binding compounds |
| JP5460858B2 (ja) * | 2009-05-05 | 2014-04-02 | エフ．ホフマン−ラ ロシュ アーゲー | イソオキサゾール−ピラゾール誘導体 |
-
2010
- 2010-02-11 TW TW099104506A patent/TW201033201A/zh unknown
- 2010-02-12 US US12/704,548 patent/US8173652B2/en not_active Expired - Fee Related
- 2010-02-16 MX MX2011007774A patent/MX2011007774A/es active IP Right Grant
- 2010-02-16 JP JP2011550540A patent/JP5478640B2/ja not_active Expired - Fee Related
- 2010-02-16 KR KR1020117021463A patent/KR101361465B1/ko not_active Expired - Fee Related
- 2010-02-16 ES ES10711603T patent/ES2431617T3/es active Active
- 2010-02-16 BR BRPI1016117A patent/BRPI1016117A8/pt not_active IP Right Cessation
- 2010-02-16 CA CA2749649A patent/CA2749649C/en not_active Expired - Fee Related
- 2010-02-16 CN CN201080008253.3A patent/CN102317270B/zh not_active Expired - Fee Related
- 2010-02-16 AU AU2010215515A patent/AU2010215515A1/en not_active Abandoned
- 2010-02-16 EP EP10711603.0A patent/EP2398782B1/en active Active
- 2010-02-16 WO PCT/EP2010/051890 patent/WO2010094669A1/en not_active Ceased
- 2010-02-16 SG SG2011058229A patent/SG173666A1/en unknown
- 2010-02-18 AR ARP100100476A patent/AR075517A1/es unknown
-
2011
- 2011-07-07 IL IL213974A patent/IL213974A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| SG173666A1 (en) | 2011-09-29 |
| US8173652B2 (en) | 2012-05-08 |
| WO2010094669A1 (en) | 2010-08-26 |
| TW201033201A (en) | 2010-09-16 |
| ES2431617T3 (es) | 2013-11-27 |
| KR101361465B1 (ko) | 2014-02-10 |
| US20100210651A1 (en) | 2010-08-19 |
| JP5478640B2 (ja) | 2014-04-23 |
| KR20110120322A (ko) | 2011-11-03 |
| CA2749649A1 (en) | 2010-08-26 |
| MX2011007774A (es) | 2011-08-12 |
| CN102317270A (zh) | 2012-01-11 |
| CN102317270B (zh) | 2014-10-08 |
| AU2010215515A1 (en) | 2011-08-11 |
| IL213974A0 (en) | 2011-08-31 |
| EP2398782A1 (en) | 2011-12-28 |
| CA2749649C (en) | 2017-04-04 |
| BRPI1016117A2 (pt) | 2016-04-12 |
| BRPI1016117A8 (pt) | 2018-01-02 |
| EP2398782B1 (en) | 2013-09-18 |
| JP2012518025A (ja) | 2012-08-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR075517A1 (es) | Derivados de isoxazol-isoxazol y de isoxazol-isotiazol | |
| AR085960A1 (es) | 1,3-oxazinas como inhibidores de la bace1 y/o de la bace2 | |
| MX2015015893A (es) | 2-fenilimidazo[1,2-a]pirimidinas como agentes formadores de imagen. | |
| AR076754A1 (es) | Dihidropirimidinas y proceso de obtencion de las mismas | |
| AR074966A1 (es) | Compuestos amino-heterociclicos | |
| DOP2014000303A (es) | 7H-PIRROLO[2,3-d] PIRIMIDINAS 4-(AMINO-SUBSTITUIDAS) NOVEDOSAS COMO INHIBIDORES DE LRRK2 | |
| AR037983A1 (es) | Derivados de pirido [2,1-a] isoquinolina | |
| AR075583A1 (es) | Derivados de isoxazol/o-piridina con eslabon etilo o etenilo | |
| AR054560A1 (es) | Espiropiperidina como inhibidores de beta-secretasa para el tratamiento de la enfermedad de alzheimer | |
| AR081045A1 (es) | Derivados de quinazolinediona como moduladores trpa1 | |
| AR083813A1 (es) | Derivados de pirazol aminopirimidina como moduladores de lrrk2 | |
| AR077935A1 (es) | Derivados de 3-amino-5 fenil-5,6-dihidro-2h-(1,4)oxazina | |
| AR086983A1 (es) | Derivados de azetidinil fenil, piridil o pirazinil carboxamida como inhibidores de jak | |
| AR081577A1 (es) | Derivados de aminopirimidina como moduladores de la lrrk2 | |
| AR063331A1 (es) | Derivados de biaril eter urea y composiciones farmaceuticas | |
| AR074358A1 (es) | Derivados de pirazina como inhibidores de la fosfodiesterasa 10 | |
| AR080785A1 (es) | Derivados de imidazo[1,2-a]pirimidina ,proceso para prepararlos e intermediarios de dicha sintesis, composiciones farmaceuticas que los contienen y uso de los mismos en el tratamiento de patologias del sistema nervioso central,tales como esquizofrenia y parkinson, entre otros. | |
| PE20151602A1 (es) | SALES DE DERIVADOS DE 2-AMINO-1-HIDROXIETIL-8-HIDROXIQUINOLIN-2(1H)-ONA QUE TIENEN ACTIVIDAD AGONISTA DEL RECEPTOR B(beta)2 ADRENERGICO ASI COMO ACTIVIDAD ANTAGONISTA DEL RECEPTOR MUSCARINICO M3 | |
| AR076551A1 (es) | Compuestos de 1-cianoetilheterociclilcarboxamida sustituida, composiciones farmaceuticas que los comprenden y su uso en el tratamiento de enfermedades mediadas por dppi | |
| AR082111A1 (es) | Furopiridinas o tienopiridinas condensadas, composiciones farmaceuticas que las contienen utiles para tratar trastornos psicoticos y del sistema nervioso central, y metodo de preparacion de las mismas | |
| AR084849A1 (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurologicos | |
| AR066562A1 (es) | Derivados de pirrol condensados; una formulacion farmaceutica en base al compuesto y su uso para preparar medicamentos | |
| PE20141553A1 (es) | Compuestos de triazolopiridina como inhibidores de la ped10a | |
| AR087710A1 (es) | Inhibidores de la quinurenina-3-monooxigenasa, sus composiciones farmaceuticas y metodos para su uso | |
| RU2007127849A (ru) | Аналоги тетрагидрохинолина в качестве мускариновых агонистов |